Fundraising Fox
🦊/Companies
Sign in

Oricell Therapeutics

Shanghai, CN · 24 employees on LinkedIn · 3 known investors

Find your way into Oricell Therapeutics

108 people in our graph share verified history with the Oricell Therapeutics team — schools, employers, funds. One of them is your warm intro.

Carlos Contiunlockedknows Helen Yang · together at China Europe International Business School (CEIBS)
×7knows the team · via Tongji University
×2knows the team · via China Europe International Business School (CEIBS)
×2knows the team · via Beijing Institute of Technology

Oricell Therapeutics (原启生物) is a clinical-stage biopharmaceutical company developing cell therapies, including CAR-T products targeting GPRC5D for relapsed/refractory multiple myeloma and GPC3 for advanced liver cancer. Based in Shanghai, it builds proprietary antibody and CAR platforms (OriAb, OriCAR) to create cancer immunotherapies for unmet oncology needs such as liver, gastric, pancreatic, biliary, and ovarian cancers.

BiotechDeep TechHealthtech

Founders & leadership

HYHelen Yang
Helen YanginCo-founder/Chairwoman/CEOHelen Yang has nearly 30 years of experience in capital operations and management at entrepreneurial and public companies, including board secretary and president roles at two public firms. She co-founded Canature Health and oversaw its IPO on ChiNext, and has served as Chairman and CEO of Oricell Therapeutics since 2015, where she established the company's antibody and CAR-T cell therapy platforms.

Investors · 3

Qiming Venture Partners✓ verifiedBeijing · $5M – $134M
Vivo Capital✓ verifiedPalo Alto · $10M – $50M
Quan CapitalShanghai

Funding

SEC filings, press & company announcements

$110M disclosed across 1 round · 2026

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series Bfiercebiotech.com · Aug 2026Oricell Therapeutics Secures $110 Million to Take on One of Oncology's Most Vexing Problems | BioPharm Internationalbiopharminternational.com · Apr 2026Oricell Therapeutics Raises Over USD 110 Million To Accelerate Global CAR T Innovationbiopharmaapac.com · Apr 2026Oricell Therapeutics Closes $110M Pre-IPO Financingfinsmes.com · Apr 2026Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors | BioPharma Divebiopharmadive.com · Apr 2026China’s Oricell raises $110M for carcinoma CAR-T plans ahead of IPO pushfiercebiotech.com · Apr 2026

Frequently asked questions

What does Oricell Therapeutics do?
Oricell Therapeutics (原启生物) is a clinical-stage biopharmaceutical company developing cell therapies, including CAR-T products targeting GPRC5D for relapsed/refractory multiple myeloma and GPC3 for advanced liver cancer. Based in Shanghai, it builds proprietary antibody and CAR platforms (OriAb, OriCAR) to create cancer immunotherapies for unmet oncology needs such as liver, gastric, pancreatic, biliary, and ovarian cancers.
Who founded Oricell Therapeutics?
Oricell Therapeutics was founded by Helen Yang.
Who are Oricell Therapeutics's investors?
Oricell Therapeutics's investors include Qiming Venture Partners, Vivo Capital, Quan Capital.
How much funding has Oricell Therapeutics raised?
Oricell Therapeutics has disclosed $110M raised across 1 round.
Where is Oricell Therapeutics headquartered?
Oricell Therapeutics is headquartered in Shanghai, CN.